＜Domestic＞
Aug 10. 2021
| Stage | Code No. (Generic name) |
Therapeutic field | Indications | Origin | Development |
|---|---|---|---|---|---|
| Launch Phase III |
NS-065/NCNP-01 (viltolarsen) |
intractable disease?orphan disease | Duchenne muscular dystrophy | Co - development: National Center of Neurology and Psychiatry |
Nippon Shinyaku |
| NDA filing | NS-304 (selexipag) |
intractable disease?orphan disease | chronic thromboembolic pulmonary hypertension |
Nippon Shinyaku | Co - development: Janssen Pharmaceutical K.K. |
| NDA filing | NS-32 (ferric derisomaltose) |
gynecology | iron deficiency anemia | Licensed - in from Pharmacosmos A/S |
Nippon Shinyaku |
| Phase III | ZX008 | intractable disease?orphan disease | Dravet syndrome Lennox-Gastaut syndrome |
Licensed - in from Zogenix, Inc. |
Zogenix, Inc. |
| Phase II | NS-304 (selexipag) |
cardiovascular | arteriosclerosis obliterans | Nippon Shinyaku | Nippon Shinyaku |
| Phase II | NS-304 (selexipag) |
orthopedics | lumbar spinal stenosis | Nippon Shinyaku | Nippon Shinyaku |
| Phase II | NS-304 (selexipag) |
cardiovascular | pediatric pulmonary arterial hypertension | Nippon Shinyaku | Co - development: Janssen Pharmaceutical K.K. |
| Phase II | NS-580 | gynecology | endometriosis | Nippon Shinyaku | Nippon Shinyaku |
| Phase I/II | NS-87 | hematologic malignancies | secondary acute myeloid leukemia | Licensed - in from Jazz Pharmaceuticals plc |
Nippon Shinyaku |
| Phase I | NS-229 | inflammatory diseases | inflammatory diseases | Nippon Shinyaku | Nippon Shinyaku |
| Preparation for Phase I | NS-917 | hematologic malignancies | relapsed/refractory acute myeloid leukemia | Licensed - in from Delta-Fly Pharma, Inc. |
Nippon Shinyaku |
| Preparation for development | NS-401 (tagraxofusp) |
hematologic malignancies | blastic plasmacytoid dendritic cell neoplasm | Licensed - in from The Menarini Group |
Nippon Shinyaku |
＜Overseas＞
| Stage | Code No. (Generic name) |
Therapeutic field | Indications | Origin | Development |
|---|---|---|---|---|---|
| US Launch Phase III |
NS-065/NCNP-01 (viltolarsen) |
intractable disease?orphan disease | Duchenne muscular dystrophy | Co - development: National Center of Neurology and Psychiatry |
Nippon Shinyaku |
| Phase III | NS-304 (selexipag) |
intractable disease?orphan disease | chronic thromboembolic pulmonary hypertension |
Nippon Shinyaku | Licensed - out to Johnson & Johnson |
| Preparation for Phase II | NS-018 (ilginatinib) |
hematologic malignancies | myelofibrosis | Nippon Shinyaku | Nippon Shinyaku |